Dr. Jose A. Morfin, MD

Dr. Morfin practices at Roseville Medical Center in Roseville, California, part of Kaiser Permanente.

Dr. Morfin's NPI, 1376528877, was assigned on December 7, 2005. Dr. Morfin graduated from David Geffen School of Medicine at UCLA in 2001. Dr. Morfin holds California license A83061.

Dr. Morfin's primary practice is Roseville Medical Center, at 1600 Eureka Road, Roseville, CA 95661 in Placer County. The practice phone is (916) 784-4000.

Dr. Morfin's primary practice is Roseville Medical Center in Roseville, California, part of Kaiser Permanente. Dr. Morfin is also affiliated with UC Davis Medical Center. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Morfin to 2 more hospitals, 5 dialysis centers, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Morfin practices, 11 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Morfin's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Morfin is board certified in internal medicine by the American Board of Internal Medicine. Dr. Morfin is licensed in California.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, fluid and electrolyte imbalances and kidney cysts among the conditions Dr. Morfin treats.

CMS data shows 1,071 Medicare services from Dr. Morfin across 12 procedure codes in 2024, for 345 Medicare patients. Medicare paid $133,392 for them.

CMS counts 345 Medicare patients who saw Dr. Morfin in 2024. The largest group is 65 to 74, with 117 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 43% are also on Medicaid. Their average risk score is 5.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Morfin's median patient age at 64, with 44% women.

In 2024, Dr. Morfin wrote 880 Medicare Part D claims for 115 patients. 77% of them were for generic drugs. CMS names the drug for 718 of them, across 24 drugs with 11 or more claims each, at $371,363 in total drug cost. In 2023, CMS named 562 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Morfin for performance year 2024, reported as part of a group. Dr. Morfin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Morfin as offering telehealth.

Dmand AI links 6 papers to Dr. Morfin in 2018. The most frequent topics are Kidney Failure, Chronic and Renal Dialysis. Dr. Morfin has published most often in Am J Kidney Dis. Dr. Morfin's most frequent co-authors are Sheru K. Kansal, MD and Peter Andrew McCullough, MD, MPH.

CMS Open Payments shows 1,422 general payments to Dr. Morfin from 17 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. AstraZeneca Pharmaceuticals LP paid the most, $433,706.

Dmand AI lists 1 award for Dr. Morfin.

Dr. Morfin graduated from David Geffen School of Medicine at UCLA in 2001. Dr. Morfin is a member of ACP and ASN.

Dr. Morfin is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.